Joint modeling of progression‐free survival and overall survival by a Bayesian normal induced copula estimation model
Authors:
- 16 July 2012
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 32 (2) , 240-254
Abstract
In cancer clinical trials, in addition to time to death (i.e., overall survival), progression‐related measurements such as progression‐free survival and time to progression are also commonly used to evaluate treatment efficacy. It is of scientific interest and importance to understand the correlations among these measurements. In this paper, we propose a Bayesian semi‐competing risks approach to jointly model progression‐related measurements and overall survival. This new model is referred to as the NICE model, which stands for the normal induced copula estimation model. Correlation among these variables can be directly derived from the joint model. In addition, when correlation exists, simulation shows that the joint model is able to borrow strength from correlated measurements, and as a consequence the NICE model improves inference on both variables. The proposed model is in a Bayesian framework that enables us to use it in various Bayesian contexts, such as Bayesian adaptive design and using posterior predictive samples to simulate future trials. We conducted simulation studies to demonstrate properties of the NICE model and applied this method to a data set from chemotherapy‐naive patients with extensive‐stage small‐cell lung cancer. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- Joint modeling of progression-free survival and death in advanced cancer clinical trialsStatistics in Medicine, 2010
- Semiparametric maximum likelihood estimation in normal transformation models for bivariate survival dataBiometrika, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and BiologicsBiotechnology Law Report, 2007
- Sample size and the probability of a successful trialPharmaceutical Statistics, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- A Weibull Model for Dependent CensoringThe Annals of Statistics, 1990
- A Model for Informative CensoringJournal of the American Statistical Association, 1989
- A Class of Bivariate DistributionsJournal of the American Statistical Association, 1965